A/T/S Drug Patent Profile
✉ Email this page to a colleague
When do A/t/s patents expire, and what generic alternatives are available?
A/t/s is a drug marketed by Taro and is included in one NDA.
The generic ingredient in A/T/S is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for A/t/s
A generic version of A/T/S was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for A/T/S
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 5,644 |
Formulation / Manufacturing: | see details |
DailyMed Link: | A/T/S at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for A/T/S
US Patents and Regulatory Information for A/T/S
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taro | A/T/S | erythromycin | SOLUTION;TOPICAL | 062405-001 | Nov 18, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |